表紙
市場調查報告書

免疫療法相關的事業合作 (2014∼2020年):交易趨勢,企業,財務資訊

Global Immunology Partnering 2014-2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 939915
出版日期 內容資訊 英文 500+ Pages
商品交期: 最快1-2個工作天內
價格
免疫療法相關的事業合作 (2014∼2020年):交易趨勢,企業,財務資訊 Global Immunology Partnering 2014-2020: Deal trends, players and financials
出版日期: 2020年06月01日內容資訊: 英文 500+ Pages
簡介

本報告提供免疫療法的治療藥開發相關近來 (2014∼2020年)的聯盟交易的趨勢相關分析,整體交易形成數量的變化,及財務方面 (付款條件) 的趨勢,主要企業 (共25家公司) 的交易形成的動向,契約條件的趨勢,各適應症 (治療標的)的趨勢等調查,近幾年主要的聯盟交易 (共700件以上)等詳細資訊彙整,為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 免疫療法相關的交易形成的趨勢

  • 簡介
  • 免疫療法相關的交易形成:近幾年趨勢
  • 免疫療法相關的交易形成:各交易類型
  • 免疫療法相關的交易形成:各業界
  • 免疫療法相關的交易形成:各開發階段
  • 免疫療法相關的交易形成:各技術種類
  • 免疫療法相關的交易形成:各適應症

第3章 免疫療法相關的事業合作:財務方面的條件

  • 簡介
  • 免疫療法相關的事業合作披露的財政條件
  • 免疫療法相關的事業合作:交易總額
  • 免疫療法相關的事業合作:預付款金
  • 免疫療法相關的事業合作:階段性付款
  • 免疫療法相關的事業合作:權利金費率

第4章 免疫療法相關的代表性交易

  • 簡介
  • 免疫療法相關的合作最活躍的企業
  • 在免疫療法的領域最活躍的企業:聯盟交易的一覽
  • 免疫療法相關的主要的交易:各契約金額

第5章 免疫療法的契約文件名錄

  • 簡介
  • 免疫療法相關的資本交易趨勢:可閱覽契約文章的交易的況

第6章 免疫療法相關的交易形成:各治療標的

  • 簡介
  • 免疫療法相關的交易形成:各治療標的

附錄

  • 附錄 (1):免疫療法相關的聯盟交易一覽,各企業名 (2014∼2020年)
  • 附錄 (2):免疫療法相關的聯盟交易一覽,各交易類型 (2014∼2020年)
  • 附錄 (3):免疫療法相關的聯盟交易一覽,各開發階段 (2014∼2020年)
  • 附錄 (4):免疫療法相關的聯盟交易一覽,各技術種類 (2014∼2020年)
目錄
Product Code: CP2224

‘The Global Immunology Partnering 2014-2020: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.

‘Global Immunology Partnering 2014 to 2020’ provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

  • Trends in Immunology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Immunology partnering agreement structure
  • Immunology partnering contract documents
  • Top Immunology deals by value
  • Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope

‘Global Immunology Partnering 2014 to 2020’ is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

‘Global Immunology Partnering 2014 to 2020’ includes:

  • Trends in Immunology dealmaking in the biopharma industry since 2014
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 700 Immunology deal records
  • The leading Immunology deals by value since 2014
  • Most active Immunology dealmakers since 2014

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In ‘Global Immunology Partnering 2014 to 2020’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

‘The Global Immunology Partnering 2014-2020 report’ provides comprehensive access to available deals and contract documents for over 700 immunology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Immunology Partnering 2014 to 2020’ provides the reader with the following key benefits:

  • In-depth understanding of Immunology deal trends since 2014
  • Access Immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Immunology partner companies
  • Comprehensive access to over 700 links to actual Immunology deals entered into by the world's biopharma companies
  • Indepth review of Immunology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Immunology opportunities
  • Uncover companies actively partnering Immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Immunology partnering by deal type
  • 2.4. Immunology partnering by industry sector
  • 2.5. Immunology partnering by stage of development
  • 2.6. Immunology partnering by technology type
  • 2.7. Immunology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Immunology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Immunology partnering
  • 3.3. Immunology partnering headline values
  • 3.4. Immunology deal upfront payments
  • 3.5. Immunology deal milestone payments
  • 3.6. Immunology royalty rates

Chapter 4 - Leading Immunology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Immunology partnering
  • 4.3. List of most active dealmakers in Immunology
  • 4.4. Top Immunology deals by value

Chapter 5 - Immunology contract document directory

  • 5.1. Introduction
  • 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Immunology therapeutic target

Appendices

  • Appendix 1 - Directory of Immunology deals by company A-Z 2014 to 2020
  • Appendix 2 - Directory of Immunology deals by deal type 2014 to 2020
  • Appendix 3 - Directory of Immunology deals by stage of development 2014 to 2020
  • Appendix 4 - Directory of Immunology deals by technology type 2014 to 2020
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Immunology partnering since 2014
  • Figure 2: Immunology partnering by deal type since 2014
  • Figure 3: Immunology partnering by industry sector since 2014
  • Figure 4: Immunology partnering by stage of development since 2014
  • Figure 5: Immunology partnering by technology type since 2014
  • Figure 6: Immunology partnering by indication since 2014
  • Figure 7: Immunology deals with a headline value
  • Figure 8: Immunology deals with upfront payment values
  • Figure 9: Immunology deals with milestone payment
  • Figure 10: Immunology deals with royalty rates
  • Figure 11: Active Immunology dealmaking activity- 2014 to 2020
  • Figure 12: Top Immunology deals by value since 2014